Search filters

List of works by William L Redmond

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

scientific article published on 8 December 2016

A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer

scientific article published on 12 December 2019

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

scientific article published on 01 July 2020

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

scientific article published on 5 April 2018

Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice

scientific article published on October 2010

Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses

scientific article published on 01 January 2007

Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth

scientific article published in 2021

B7-2 (CD86) controls the priming of autoreactive CD4 T cell response against pancreatic islets

article

CD8+ T cell tolerance in nonobese diabetic mice is restored by insulin-dependent diabetes resistance alleles.

scientific article published in August 2005

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

scientific article

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.

scientific article

Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer.

scientific article published on 7 November 2013

Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8+ T cells.

scientific article published on 26 July 2016

Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts.

scientific article published on 17 March 2014

Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity.

scientific article published on 7 November 2013

Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity

scientific article published on 11 November 2013

Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cells

scientific article

Cutting edge: T cell-mediated pathology in murine Lyme borreliosis.

scientific article published on June 2000

Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist

scientific article published on December 2007

Deletion of Naive CD8 T Cells Requires Persistent Antigen and Is Not Programmed by an Initial Signal from the Tolerogenic APC

scientific article published on 01 December 2003

Distinct Requirements for Deletion versus Anergy during CD8 T Cell Peripheral Tolerance In Vivo

scientific article published on 01 February 2005

Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression

scientific article (publication date: 2012)

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.

scientific article published on 12 July 2016

Editorial: Advances in Combination Tumor Immunotherapy

scientific article

How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy.

scientific article published on 21 June 2016

Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy

scientific article published on 01 January 2019

Implementation and Validation of an Automated Flow Cytometry Analysis Pipeline for Human Immune Profiling

scientific article published on 20 December 2018

Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade.

scientific article published on 4 June 2016

Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8+ T Cell Development

scientific article published on 26 August 2020

Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo

scientific article

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer

scientific article published on 01 May 2020

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.

scientific article

OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor

scientific article published in July 2008

Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists

scientific article published on 10 April 2018

Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen.

scientific article

Professional development session for early career scientists at SITC 2012.

scientific article published on 27 June 2013

Signaling through OX40 enhances antitumor immunity

scientific article published on October 2010

The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen

scientific article

The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor

scientific article

The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment.

scientific article

Paulina is supported by:

About Paulina

Help